Increasing prevalence of gastrointestinal disorders augmenting the demand for Proton Pump Inhibitors (PPI)

Proton Pump Inhibitors (PPI) are the common class of drugs for the relief of mild gastroesophageal reflux disease and heartburn. They work by temporarily blocking the site of stomach acid secretion in the parietal muscle of the esophagus. PPI's are usually prescribed by a doctor who assesses the severity of the acid problem and will prescribe PPI's that are effective and safe for patients. Proton pump inhibitor drugs are available to buy over the counter without a prescription

Request Here PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/4225

Proton pump inhibitors are sometimes used to replace more long term treatment like antacids, beta-blockers, or proton pump inhibitors that are not successful in treating acid reflux. They can be used as an adjunct to traditional treatment and have been recommended for people with GERD, acid reflux, and heartburn problems. However, their long-term use has not been fully assessed.

The growing prevalence of various gastrointestinal disorders such as hyperacidity is driving the market growth of Proton Pump Inhibitors. According to the National Health Interview Survey 2018, 14.8 million adults were diagnosed with ulcers and 5.9% of adults were diagnosed with ulcers. The growing prevalence of obesity in adults and adolescents is another major factor that is increasing cases of gastroesophageal reflux disease. According to the Hindawi, Obesity is primary among the medical disorders composing metabolic syndrome and is associated with many gastrointestinal diseases.

From the geographical point of view, North America is expected to gain significant growth over the forecast period and this is attributed to high presence of the obese population in the region. According to the National Center for Chronic Disease Prevention and Health Promotion, the prevalence of obesity was 42.4% in 2017~2018. From 1999–2000 through 2017–2018, the prevalence of obesity increased from 30.5% to 42.4%, and the prevalence of severe obesity increased from 4.7% to 9.2%.

Key Developments:

In April 2018, AstraZeneca K.K. and Daiichi Sankyo Company Limited together announced the launch of proton pump inhibitor Nexium® 10 mg and 20 mg Granules for Suspension, Sachet, (generic name: esomeprazole magnesium hydrate).

In November 2020, Daewoong Pharmaceutical announced the Publication of Novel P-CAB Fexuprazan Phase 1 Bridging Study. Bridging study results, demonstrate no racial differences exist in pharmacokinetic and pharmacodynamic properties of fexuprazan. Fexuprazan is a potassium-competitive acid blocker (P-CAB), which reversibly blocks the proton pump that secretes gastric acids from the stomach wall. It is a novel drug investigated for gastroesophageal reflux disease.

Flat USD 2000 OFF

Buy This Research Study Report @ https://www.coherentmarketinsights.com/promo/buynow/4225

Top Players Are: AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Santarus, Inc., Wyeth, LLC, Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Sanofi S.A., Aurobindo Pharma, Perrigo Company plc, Dr. Reddy's Laboratories

There is Multiple Chapter to display the Global Proton Pump Inhibitors Market some of them As Follow

Chapter 1, Definition, Specifications and Classification of Proton Pump Inhibitors, Applications of Proton Pump Inhibitors, Market Segment by Regions;
Chapter 2, Manufacturing Cost Structure, Raw Materials, and Suppliers, Manufacturing Process, Industry Chain Structure;
Chapter 3, Technical Data and Manufacturing Plants Analysis of Proton Pump Inhibitors, Capacity, and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;
Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);
Chapter 5 and 6, Regional Market Analysis that includes the United States, China, Europe, Japan, Korea & Taiwan, Proton Pump Inhibitors Segment Market Analysis (by Type);
Chapter 7 and 8, The Proton Pump Inhibitors Segment Market Analysis (by Application) Major Manufacturers Analysis of Proton Pump Inhibitors;
Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Natural preservative, Chemical preservative, Market Trend by Application;
Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;
Chapter 11, The Consumers Analysis of Global Proton Pump Inhibitors;
Chapter 12, Proton Pump Inhibitors Research Findings and Conclusion, Appendix, methodology and data source;
Chapter 13, 14 and 15, Proton Pump Inhibitors sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Look Into Some Latest Insights

Interventional Pain Management Market - https://www.medgadget.com/2021/07/interventional-pain-management-market-trends-in-2021-industry-share-size-analysis-growth-insights-opportunities-business-forecast-by-2026-exclusive-reportage-by-cmi.html

Bone Sonometer Market - https://www.medgadget.com/2021/07/bone-sonometer-market-size-is-projected-to-reach-us-1-2-billion-at-a-cagr-of-5-32-owing-to-technological-developments-in-healthcare-by-2026.html

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.